Dr. Jonathan C Roberts, MD
Claim this profileBleeding and Clotting Disorders Institute
Studies Von Willebrand Disease
Studies Hemophilia
9 reported clinical trials
10 drugs studied
Area of expertise
1Von Willebrand Disease
VWF collagen binding positive
VWF activity positive
VWF antigen positive
2Hemophilia
VWF collagen binding positive
VWF activity positive
VWF antigen positive
Affiliated Hospitals
Clinical Trials Jonathan C Roberts, MD is currently running
Natural History Study
for Blood Disorders
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this increase in potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. ATHN Transcends is a cohort study to determine the safety, effectiveness, and practice of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. The study consists of 7 cohorts with additional study "arms" and "modules" branching off from the cohorts. The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7)
Recruiting1 award N/A1 criteria
VWF Replacement Therapy
for Von Willebrand Disease
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding. This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum period, followed by levels of 50-100% for 5-10 days after delivery, depending upon the route of delivery. The primary objective is to document the rate of primary postpartum hemorrhage (PPH). The secondary objective is to document further effectiveness outcomes and safety.
Recruiting2 awards N/A3 criteria
More about Jonathan C Roberts, MD
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jonathan C Roberts, MD has experience with
- Emicizumab
- Wilate
- Placebo
- CLBS16
- Antihemophilic Factor (Recombinant)
- Von Willebrand Factor (Recombinant)
Breakdown of trials Jonathan C Roberts, MD has run
Von Willebrand Disease
Coronary Artery Disease
Microvascular Angina
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jonathan C Roberts, MD specialize in?
Jonathan C Roberts, MD focuses on Von Willebrand Disease and Hemophilia. In particular, much of their work with Von Willebrand Disease has involved VWF collagen binding positive patients, or patients who are VWF activity positive.
Is Jonathan C Roberts, MD currently recruiting for clinical trials?
Yes, Jonathan C Roberts, MD is currently recruiting for 5 clinical trials in Peoria Illinois. If you're interested in participating, you should apply.
Are there any treatments that Jonathan C Roberts, MD has studied deeply?
Yes, Jonathan C Roberts, MD has studied treatments such as Emicizumab, Wilate, Placebo.
What is the best way to schedule an appointment with Jonathan C Roberts, MD?
Apply for one of the trials that Jonathan C Roberts, MD is conducting.
What is the office address of Jonathan C Roberts, MD?
The office of Jonathan C Roberts, MD is located at: Bleeding and Clotting Disorders Institute, Peoria, Illinois 61614 United States. This is the address for their practice at the Bleeding and Clotting Disorders Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.